The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
Deniz Can Güven, Emre Yekedüz, Enes Erul, Satı Coşkun Yazgan, Taha Koray Şahin, Göktürk Karataş, Sercan Aksoy, Mustafa Erman 等 11 位
Hacettepe University Ankara University Istinye University Liv Hospital
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Objective: Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation with ICIs. However, real-life data on the benefit of TBP is scarce, especially from the limited resource settings. Therefore, we aimed to investigate the survival benefit of TBP with ICIs in patients with advanced tumors from a limited resource setting.Methods: For this multicenter study, we included 282 patients treated with ICIs and radiological progression according to RECIST 1.1 criteria. The evaluated post-progression survival according to the use of TBP (TBP and non-TBP groups) with univariate and multivariate analyses.Results: 82 (29.1%) of 282 patients continued on ICIs following the initial progression event. In multivariate analyses, patients in the TBP group had improved post-progression survival compared to non-TBP (13.18 vs. 4.63 months, HR: 0.500, 95% CI: 0.349-0.717, p<0.001). The benefit of the TBP was independent of the tumor type, treatment line, and patient age. Furthermore, TBP with ICIs was associated with improved post-progression survival (HR: 0.600, 95% CI: 0.380-0.947, p=0.028) in the additional analyses after excluding the patients with no further treatment after progression in the non-TBP arm.Conclusions: In this study, we observed that patients receiving ICIs beyond progression had considerably longer survival. Continuation of ICIs after progression should be kept in mind as a reasonable management option for patients with advanced cancer, specifically for patients with limited alternative options.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Cancer Immunotherapy and Biomarkers
Medical Imaging Techniques and Applications · Immunotherapy and Immune Responses
参考文献 54
此处列出前 3 条
引用本文 9
按被引量排序,此处列出前 3 条